Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 7,590 Shares

by · The Cerbat Gem

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Traci Umberger sold 7,590 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.86, for a total transaction of $181,097.40. Following the completion of the transaction, the insider owned 199,405 shares of the company’s stock, valued at approximately $4,757,803.30. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

NASDAQ:KMTS traded up $1.16 during midday trading on Monday, reaching $23.99. The company had a trading volume of 373,728 shares, compared to its average volume of 404,856. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock’s fifty day simple moving average is $22.62 and its 200-day simple moving average is $22.48.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in Kestra Medical Technologies in the first quarter valued at approximately $11,036,000. Woodline Partners LP purchased a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $2,510,000. Jane Street Group LLC acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $756,000. Geode Capital Management LLC raised its position in Kestra Medical Technologies by 718.5% in the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after purchasing an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Kestra Medical Technologies during the 2nd quarter worth $256,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KMTS shares. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. BTIG Research upped their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $27.83.

Get Our Latest Stock Analysis on Kestra Medical Technologies

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Featured Articles